XML 58 R31.htm IDEA: XBRL DOCUMENT v3.22.0.1
Segmental information - Consolidated income statement (Details) - GBP (£)
£ in Millions
 4 Months Ended 6 Months Ended
Dec. 31, 2021
Dec. 31, 2021
Dec. 31, 2020
Disclosure of operating segments [line items]      
Sales   £ 11,753 £ 10,436
Net sales      
At budgeted exchange rates   8,066 7,130
Acquisitions and disposals   21 12
SC&P allocation   0 0
Retranslation to actual exchange rates   (130) (268)
Net sales   7,957 6,874
Operating profit/(loss)      
At budgeted exchange rates   2,774 2,426
Acquisitions and disposals   (17) (9)
SC&P allocation   0 0
Fair value remeasurement of contingent considerations, equity option and earn out arrangements   23  
Fair value remeasurement of contingent considerations     (11)
Fair value remeasurement of biological assets in operating profit   3 3
Retranslation to actual exchange rates   (40) (153)
Operating profit/(loss) before exceptional items     2,256
Exceptional items     (17)
Operating profit/(loss)   2,743 2,239
Non-operating items   (31) 5
Net finance charges   (180) (200)
Share of after tax results of associates and joint ventures   190 154
Profit before taxation   2,722 2,198
Percentage of calendar year net sales that occur in the last four months 44.00%    
Operating segments      
Disclosure of operating segments [line items]      
Sales   11,730 10,425
Net sales      
At budgeted exchange rates   8,043 7,119
Acquisitions and disposals   21 12
SC&P allocation   0 0
Retranslation to actual exchange rates   (130) (268)
Net sales   7,934 6,863
Operating profit/(loss)      
At budgeted exchange rates   2,906 2,524
Acquisitions and disposals   (17) (9)
SC&P allocation   0 0
Fair value remeasurement of contingent considerations, equity option and earn out arrangements   23  
Fair value remeasurement of contingent considerations     (11)
Fair value remeasurement of biological assets in operating profit   3 3
Retranslation to actual exchange rates   (47) (157)
Operating profit/(loss) before exceptional items     2,350
Exceptional items     (17)
Operating profit/(loss)   2,868 2,333
Eliminate intersegment sales      
Disclosure of operating segments [line items]      
Sales   (972) (785)
Net sales      
At budgeted exchange rates   (979) (786)
Acquisitions and disposals   0 0
SC&P allocation   0 0
Retranslation to actual exchange rates   7 1
Net sales   (972) (785)
Corporate and other      
Disclosure of operating segments [line items]      
Sales   23 11
Net sales      
At budgeted exchange rates   23 11
Acquisitions and disposals   0 0
SC&P allocation   0 0
Retranslation to actual exchange rates   0 0
Net sales   23 11
Operating profit/(loss)      
At budgeted exchange rates   (132) (98)
Acquisitions and disposals   0 0
SC&P allocation   0 0
Fair value remeasurement of contingent considerations, equity option and earn out arrangements   0  
Fair value remeasurement of contingent considerations     0
Fair value remeasurement of biological assets in operating profit   0 0
Retranslation to actual exchange rates   7 4
Operating profit/(loss) before exceptional items     (94)
Exceptional items     0
Operating profit/(loss)   (125) (94)
North America | Operating segments      
Disclosure of operating segments [line items]      
Sales   3,257 3,022
Net sales      
At budgeted exchange rates   2,959 2,790
Acquisitions and disposals   18 7
SC&P allocation   6 5
Retranslation to actual exchange rates   (19) (101)
Net sales   2,964 2,701
Operating profit/(loss)      
At budgeted exchange rates   1,288 1,325
Acquisitions and disposals   (16) (9)
SC&P allocation   10 (13)
Fair value remeasurement of contingent considerations, equity option and earn out arrangements   5  
Fair value remeasurement of contingent considerations     (4)
Fair value remeasurement of biological assets in operating profit   0 0
Retranslation to actual exchange rates   8 (73)
Operating profit/(loss) before exceptional items     1,226
Exceptional items     0
Operating profit/(loss)   1,295 1,226
Europe | Operating segments      
Disclosure of operating segments [line items]      
Sales   3,178 2,727
Net sales      
At budgeted exchange rates   1,782 1,442
Acquisitions and disposals   3 0
SC&P allocation   29 21
Retranslation to actual exchange rates   (62) (20)
Net sales   1,752 1,443
Operating profit/(loss)      
At budgeted exchange rates   647 461
Acquisitions and disposals   (1) 0
SC&P allocation   (23) 0
Fair value remeasurement of contingent considerations, equity option and earn out arrangements   21  
Fair value remeasurement of contingent considerations     (7)
Fair value remeasurement of biological assets in operating profit   0 0
Retranslation to actual exchange rates   (31) (8)
Operating profit/(loss) before exceptional items     446
Exceptional items     (17)
Operating profit/(loss)   613 429
Asia Pacific | Operating segments      
Disclosure of operating segments [line items]      
Sales   2,999 2,837
Net sales      
At budgeted exchange rates   1,544 1,418
Acquisitions and disposals   0 0
SC&P allocation   5 4
Retranslation to actual exchange rates   (18) (27)
Net sales   1,531 1,395
Operating profit/(loss)      
At budgeted exchange rates   454 391
Acquisitions and disposals   0 0
SC&P allocation   (3) 0
Fair value remeasurement of contingent considerations, equity option and earn out arrangements   0  
Fair value remeasurement of contingent considerations     0
Fair value remeasurement of biological assets in operating profit   0 0
Retranslation to actual exchange rates   0 (5)
Operating profit/(loss) before exceptional items     386
Exceptional items     0
Operating profit/(loss)   451 386
Africa | Operating segments      
Disclosure of operating segments [line items]      
Sales   1,244 1,064
Net sales      
At budgeted exchange rates   888 790
Acquisitions and disposals   0 5
SC&P allocation   2 2
Retranslation to actual exchange rates   (22) (52)
Net sales   868 745
Operating profit/(loss)      
At budgeted exchange rates   192 124
Acquisitions and disposals   0 0
SC&P allocation   (1) 0
Fair value remeasurement of contingent considerations, equity option and earn out arrangements   0  
Fair value remeasurement of contingent considerations     0
Fair value remeasurement of biological assets in operating profit   0 0
Retranslation to actual exchange rates   (15) (29)
Operating profit/(loss) before exceptional items     95
Exceptional items     0
Operating profit/(loss)   176 95
Latin America and Caribbean | Operating segments      
Disclosure of operating segments [line items]      
Sales   1,052 775
Net sales      
At budgeted exchange rates   822 641
Acquisitions and disposals   0 0
SC&P allocation   6 6
Retranslation to actual exchange rates   (9) (68)
Net sales   819 579
Operating profit/(loss)      
At budgeted exchange rates   333 246
Acquisitions and disposals   0 0
SC&P allocation   9 (10)
Fair value remeasurement of contingent considerations, equity option and earn out arrangements   (3)  
Fair value remeasurement of contingent considerations     0
Fair value remeasurement of biological assets in operating profit   3 3
Retranslation to actual exchange rates   (9) (42)
Operating profit/(loss) before exceptional items     197
Exceptional items     0
Operating profit/(loss)   333 197
SC&P | Operating segments      
Disclosure of operating segments [line items]      
Sales   972 785
Net sales      
At budgeted exchange rates   1,027 824
Acquisitions and disposals   0 0
SC&P allocation   (48) (38)
Retranslation to actual exchange rates   (7) (1)
Net sales   972 785
Operating profit/(loss)      
At budgeted exchange rates   (8) (23)
Acquisitions and disposals   0 0
SC&P allocation   8 23
Fair value remeasurement of contingent considerations, equity option and earn out arrangements   0  
Fair value remeasurement of contingent considerations     0
Fair value remeasurement of biological assets in operating profit   0 0
Retranslation to actual exchange rates   0 0
Operating profit/(loss) before exceptional items     0
Exceptional items     0
Operating profit/(loss)   £ 0 £ 0